Literature DB >> 22669436

[Botulinum toxin for the treatment of secretory disorders of the head and neck area].

A Steffen1.   

Abstract

Botulinum toxin can be used for the temporary blockade of secretory glands in the head and neck area. Botulinum toxin is increasingly the therapy of choice for the treatment of Frey's syndrome and gustatory tearing, and it is gaining attention for hypersalivation therapy. For nasal hypersecretion, this drug has a very specific use. In comparison to the treatment of skeletal muscles, the individual effect and its duration are more difficult to predict. All indications presented here are for off-label use; therefore, careful counseling and informed consent are necessary. With botulinum toxin, for several diseases, as new treatment options are opening up, well-founded knowledge about the indications and treatment course is important for the ENT surgeon.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22669436     DOI: 10.1007/s00106-012-2498-x

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  25 in total

Review 1.  [Drooling in neuropediatric patients].

Authors:  A Steffen; S Ortfeld; R Schönweiler
Journal:  Klin Padiatr       Date:  2011-01-26       Impact factor: 1.349

2.  Botulinum toxin treatment for hyperlacrimation secondary to aberrant regenerated seventh nerve palsy or salivary gland transplantation.

Authors:  David J Keegan; Gerd Geerling; John P Lee; Glen Blake; J Richard Collin; Gordon T Plant
Journal:  Br J Ophthalmol       Date:  2002-01       Impact factor: 4.638

3.  [Rhinosinusitis guidelines of the German Society for Otorhinolaryngology, Head and Neck Surgery].

Authors:  B A Stuck; C Bachert; P Federspil; W Hosemann; L Klimek; R Mösges; O Pfaar; C Rudack; H Sitter; M Wagenmann; K Hörmann
Journal:  HNO       Date:  2007-10       Impact factor: 1.284

4.  Up-to-date report of botulinum toxin type A treatment in patients with gustatory sweating (Frey's syndrome).

Authors:  R Laskawi; C Drobik; C Schönebeck
Journal:  Laryngoscope       Date:  1998-03       Impact factor: 3.325

5.  Submandibular duct relocation for drooling: a 10-year experience with 194 patients.

Authors:  W S Crysdale; A White
Journal:  Otolaryngol Head Neck Surg       Date:  1989-07       Impact factor: 3.497

6.  Successful management of drooling with botulinum toxin A in neurologically disabled children.

Authors:  M Ellies; S Rohrbach-Volland; C Arglebe; B Wilken; R Laskawi; F Hanefeld
Journal:  Neuropediatrics       Date:  2002-12       Impact factor: 1.947

7.  Surgical management of pleomorphic adenomas of the parotid gland: a follow-up study of three methods.

Authors:  R Laskawi; T Schott; M Mirzaie-Petri; M Schroeder
Journal:  J Oral Maxillofac Surg       Date:  1996-10       Impact factor: 1.895

8.  Investigation of the effects of intranasal botulinum toxin type A and ipratropium bromide nasal spray on nasal hypersecretion in idiopathic rhinitis without eosinophilia.

Authors:  Tarik Sapci; Sara Yazici; M Fatih Evcimik; Ziya Bozkurt; Ahmet Karavus; Bayram Ugurlu; Emre Ozkurt
Journal:  Rhinology       Date:  2008-03       Impact factor: 3.681

9.  A comparison of the effects of botulinum toxin A and steroid injection on nasal allergy.

Authors:  Tae Yong Yang; Yoon Gun Jung; Young Hyo Kim; Tae Young Jang
Journal:  Otolaryngol Head Neck Surg       Date:  2008-09       Impact factor: 3.497

10.  Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis.

Authors:  Saskia Rohrbach; Katharina Junghans; Sibylle Köhler; Rainer Laskawi
Journal:  Head Face Med       Date:  2009-10-16       Impact factor: 2.151

View more
  1 in total

1.  [Rhinorrhea following laryngectomy : Treatment with botulinum toxin type A.]

Authors:  J Winterhoff; A Gehrt; C Matthias; R Laskawi
Journal:  HNO       Date:  2013-11-16       Impact factor: 1.284

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.